20-valent pneumococcal conjugate vaccine - Biologic Drug Details

Summary for 20-valent pneumococcal conjugate vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for 20-valent pneumococcal conjugate vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Pneumococcal Vaccine
Chemical Structure	Pneumococcal Vaccines Vaccines, Conjugate Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for 20-valent pneumococcal conjugate vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for 20-valent pneumococcal conjugate vaccine Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for 20-valent pneumococcal conjugate vaccine Derived from Patent Text Search

No patents found based on company disclosures

20-valent pneumococcal conjugate vaccine Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the 20-Valent Pneumococcal Conjugate Vaccine

Introduction

The 20-valent pneumococcal conjugate vaccine (PCV20) is a significant advancement in the fight against pneumococcal diseases, which include invasive pneumococcal disease (IPD), pneumonia, and otitis media. This vaccine, exemplified by Pfizer's Vaxneuvance, has garnered substantial attention due to its broad serotype coverage and potential to reduce the burden of pneumococcal infections globally.

Market Size and Growth

The global pneumococcal vaccines market, which includes the 20-valent conjugate vaccine, is projected to experience robust growth. In 2024, the market is estimated to be valued at approximately USD 8.92 billion and is expected to reach USD 12.51 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.9% during this period[1][3].

Key Drivers of Market Growth

Several factors are driving the growth of the pneumococcal vaccines market, including:

Increasing Prevalence of Pneumococcal Diseases

The high prevalence of pneumonia, particularly among children and older adults, is a significant driver. For instance, UNICEF data indicates that around 2,000 children are affected by pneumonia daily, highlighting the urgent need for effective vaccines[3].

Advancements in Vaccine Technologies

The development and approval of higher valent conjugate vaccines, such as PCV20, offer broader serotype coverage and higher efficacy against pneumococcal diseases. This technological advancement is a key trend in the market[1][3].

Government Support and Immunization Programs

Governments and global health organizations, such as Gavi, the Vaccine Alliance, have increased support for immunization programs, expanding access to pneumococcal vaccines in developing countries. This support is crucial for market growth[1].

Segment Analysis

Conjugate Vaccine Segment

The conjugate vaccine segment, which includes PCV20, is expected to dominate the market due to its high efficacy. This segment is anticipated to witness substantial growth driven by ongoing developments and strategic initiatives by market players[1][3].

Product-Specific Performance

Pfizer's Vaxneuvance (PCV20) and Prevnar 20 are notable products in this segment. Prevnar 20, for example, was approved by the FDA in April 2023 for preventing IPD and otitis media in infants and children, further boosting market growth[5].

Cost-Effectiveness and Health Outcomes

Studies have shown that PCV20 is highly cost-effective compared to lower valent vaccines. A cost-effectiveness analysis indicated that vaccination with PCV20 prevents additional cases of IPD, pneumonia, and otitis media, resulting in significant reductions in medical care costs and improvements in quality-adjusted life-years (QALYs)[2].

Competitive Landscape

The market is characterized by intense competition among major pharmaceutical companies such as Pfizer, Sanofi, and SK bioscience. These companies are investing heavily in the development and commercialization of novel pneumococcal vaccines. For instance, Sanofi and SK bioscience are advancing their 21-valent conjugate vaccine candidate, which could offer even broader serotype coverage[5].

Distribution and Access

The distribution of pneumococcal vaccines is facilitated through various channels, including government programs, private healthcare providers, and global health organizations. Initiatives such as India's nationwide rollout of PCV under the Universal Immunisation Programme (UIP) are examples of efforts to increase access to these vaccines[3].

Challenges and Limitations

Despite the positive outlook, the market faces challenges such as the high costs associated with vaccine development and the potential side effects of vaccines. These factors can impact market growth and adoption rates[1].

Future Outlook

The future of the 20-valent pneumococcal conjugate vaccine market looks promising, driven by ongoing research, government initiatives, and the increasing need for effective vaccines. As new products and technologies emerge, the market is expected to continue its upward trajectory.

Key Takeaways

• The global pneumococcal vaccines market is projected to grow at a CAGR of 4.9% from 2024 to 2031.
• The conjugate vaccine segment, particularly PCV20, is expected to dominate the market.
• Government support and immunization programs are crucial for market growth.
• The cost-effectiveness of PCV20 is a significant factor in its adoption.
• Ongoing research and development of new vaccines will continue to drive market expansion.

FAQs

1. What is the projected market size of the global pneumococcal vaccines market by 2031? The global pneumococcal vaccines market is expected to reach USD 12.51 billion by 2031[1].

2. What is the significance of the 20-valent pneumococcal conjugate vaccine? The 20-valent pneumococcal conjugate vaccine offers broader serotype coverage and higher efficacy against pneumococcal diseases compared to lower valent vaccines[1][3].

3. How does government support impact the pneumococcal vaccines market? Government support through expanded immunization programs and funding from global health organizations significantly increases access to pneumococcal vaccines, driving market growth[1].

4. What are the key challenges facing the pneumococcal vaccines market? High costs associated with vaccine development and potential side effects are key challenges facing the market[1].

5. Which companies are leading the development of new pneumococcal vaccines? Companies such as Pfizer, Sanofi, and SK bioscience are at the forefront of developing new pneumococcal vaccines, including higher valent conjugate vaccines[5].

Cited Sources:

1. Biospace - Pneumococcal Vaccines Market to hit US$ 12.51 billion by 2031[1].
2. ISPOR - Cost-Effectiveness Analysis of 20-Valent Pneumococcal Conjugate Vaccine[2].
3. Mordor Intelligence - Pneumococcal Vaccine Market Size & Share Analysis[3].
4. Drug Patent Watch - PREVNAR 20 Patents and Market Size[4].
5. Grand View Research - Pneumococcal Vaccine Market Size And Share Report, 2030[5].